ZIMMER BIOMET HOLDINGS, INC. shareholders rejected Shareholder proposal on Independent Board Chairman at the 2026-05-22 meeting.
“• rejected a shareholder proposal on Independent Board Chairman (Proposal 4).”
ZIMMER BIOMET HOLDINGS, INC. — fact timeline
Source-grounded facts extracted from ZIMMER BIOMET HOLDINGS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ZIMMER BIOMET HOLDINGS, INC. shareholders approved Advisory vote to approve named executive officer compensation at the 2026-05-22 meeting.
“• approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s proxy statement (Proposal 3);”
ZIMMER BIOMET HOLDINGS, INC. shareholders approved Ratification of the Audit Committee’s appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2026 at the 2026-05-22 meeting.
“• ratified the Audit Committee’s appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2026 (Proposal 2);”
ZIMMER BIOMET HOLDINGS, INC. shareholders approved Election of ten directors for one-year terms ending at the 2027 annual meeting at the 2026-05-22 meeting.
“• elected ten (10) directors for one-year terms ending at the 2027 annual meeting of shareholders (Proposal 1);”
ZIMMER BIOMET HOLDINGS, INC. reported the fiscal year ending December 31, 2026 results: EPS $8.40 - $8.55. Guidance raised.
“The Company is updating its full-year 2026 financial guidance as follows:”
ZIMMER BIOMET HOLDINGS, INC. reported the quarter ended March 31, 2026 results: revenue $2.087 billion, net income $238.1 million, EPS $1.22.
“The Company reported first quarter net sales of $2.087 billion, an increase of 9.3% over the prior year period, an increase of 6.8% on a constant currency 1 basis and an increase of 2.9% on an organic constant currency 1 basis.”
Paul Stellato was appointed as interim Chief Financial Officer at ZIMMER BIOMET HOLDINGS, INC..
“Paul Stellato, Vice President, Controller and Chief Accounting Officer, has been appointed to act, along with continuing to serve in his current role, as the Company’s interim Chief Financial Officer, effective upon Mr. Upadhyay’s departure, until a permanent successor is named.”
Suketu Upadhyay resigned as Chief Financial Officer and Executive Vice President – Finance, Operations and Supply Chain at ZIMMER BIOMET HOLDINGS, INC..
“On April 22, 2026, Suketu Upadhyay informed Zimmer Biomet Holdings, Inc. (the “Company”) of his intention to resign from the position of Chief Financial Officer and Executive Vice President – Finance, Operations and Supply Chain of the Company, effective as of April 28, 2026, to pursue a new professional opportunity.”
ZIMMER BIOMET HOLDINGS, INC. incurred revolving credit of $1.0 billion with JPMorgan Chase Bank, N.A. at floating rates based upon either an adjusted Term SOFR for the applicable intere maturing June 26, 2026.
“The 364-Day Revolving Credit Agreement, dated as of June 27, 2025, among the Company, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the “364-Day Credit Agreement”), is an unsecured revolving credit facility in the principal amount of $1.0 billion (the “364-Day Revolving Facility”).”
ZIMMER BIOMET HOLDINGS, INC. incurred revolving credit of $1.5 billion with JPMorgan Chase Bank, N.A. at floating rates based upon either an adjusted Term SOFR for the applicable intere maturing June 27, 2030.
“the Company, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the “Five-Year Credit Agreement”), is a five-year unsecured revolving facility of $1.5 billion (the “Five-Year Revolving Facility”). The Five-Year Credit Agreement will mature on June 27, 2030, with two one-year extensions exercisable at the Company’s discretion and”
ZIMMER BIOMET HOLDINGS, INC.: Amended Restated Certificate of Incorporation to limit personal liability of certain officers for monetary damages for breach of duty of care as permitted under Delaware law (effective 2025-05-29).
“At the Annual Meeting, the Company’s shareholders approved an amendment (the “Amendment”) to the Company’s Restated Certificate of Incorporation (the “Charter”).”
Mark Bezjak departed as President, Americas at ZIMMER BIOMET HOLDINGS, INC..
“Mark Bezjak, President, Americas, will continue to hold such office but will cease to be an executive officer of the Company at the time Mr. Thornal joins the Company.”
Kevin Thornal was appointed as Group President, Global Businesses and the Americas at ZIMMER BIOMET HOLDINGS, INC..
“Kevin Thornal has been appointed to the newly-created position of Group President, Global Businesses and the Americas of the Company, effective July 1, 2025.”
Michael Farrell was appointed as Lead Independent Director at ZIMMER BIOMET HOLDINGS, INC..
“has appointed Michael Farrell to be the Lead Independent Director of the Board, effective upon the commencement of Mr. Tornos’ service as Chairman.”
Ivan Tornos was appointed as Chairman of the Board at ZIMMER BIOMET HOLDINGS, INC..
“has appointed Ivan Tornos, the Company’s President, Chief Executive Officer and a director, as the Chairman of the Board, effective on May 29, 2025”
Christopher Begley departed as Chairman of the Board at ZIMMER BIOMET HOLDINGS, INC..
“Christopher Begley, the Company’s Chairman of the Board, is not eligible for nomination by the Board for election as a director at the 2025 Annual Meeting and will retire from the Board when his current term expires at such meeting.”
ZIMMER BIOMET HOLDINGS, INC. incurred senior notes of $600,000,000 with noteholders at 5.500% maturing February 19, 2035.
“On February 19, 2025, Zimmer Biomet Holdings, Inc. (the “Company”) completed its previously announced issuance of $600,000,000 aggregate principal amount of its 4.700% notes due 2027 (the “2027 Notes”), $550,000,000 aggregate principal amount of its 5.050% notes due 2030 (the “2030 Notes”) and $600,000,000 aggregate principal amount of its 5.500% notes due 2035 (the “2035 Notes” and, together with the 2027 Notes and the 2030 Notes, the “Notes”).”
ZIMMER BIOMET HOLDINGS, INC. incurred senior notes of $550,000,000 with noteholders at 5.050% maturing February 19, 2030.
“On February 19, 2025, Zimmer Biomet Holdings, Inc. (the “Company”) completed its previously announced issuance of $600,000,000 aggregate principal amount of its 4.700% notes due 2027 (the “2027 Notes”), $550,000,000 aggregate principal amount of its 5.050% notes due 2030 (the “2030 Notes”) and $600,000,000 aggregate principal amount of its 5.500% notes due 2035 (the “2035 Notes” and, together with the 2027 Notes and the 2030 Notes, the “Notes”).”
ZIMMER BIOMET HOLDINGS, INC. incurred senior notes of $600,000,000 with noteholders at 4.700% maturing February 19, 2027.
“On February 19, 2025, Zimmer Biomet Holdings, Inc. (the “Company”) completed its previously announced issuance of $600,000,000 aggregate principal amount of its 4.700% notes due 2027 (the “2027 Notes”), $550,000,000 aggregate principal amount of its 5.050% notes due 2030 (the “2030 Notes”) and $600,000,000 aggregate principal amount of its 5.500% notes due 2035 (the “2035 Notes” and, together with the 2027 Notes and the 2030 Notes, the “Notes”).”
Devdatt Kurdikar was appointed as Director at ZIMMER BIOMET HOLDINGS, INC..
“On June 20, 2024, the Board of Directors (the “Board”) of Zimmer Biomet Holdings, Inc. (the “Company”), upon the recommendation of the Corporate Governance Committee, increased the size of the Board from ten members to eleven members and appointed Devdatt Kurdikar to fill the resulting vacancy”
ZIMMER BIOMET HOLDINGS, INC. shareholders approved Approval of the Amended Employee Stock Purchase Plan at the 2024-05-10 meeting.
“Proposal 4 – Approval of the Amended Employee Stock Purchase Plan For Against Abstain Broker Non-Votes 171,503,181 603,453 178,037 14,430,099”
ZIMMER BIOMET HOLDINGS, INC. shareholders approved Advisory Vote to Approve Named Executive Officer Compensation at the 2024-05-10 meeting.
“Proposal 3 – Advisory Vote to Approve Named Executive Officer Compensation For Against Abstain Broker Non-Votes 156,440,914 15,603,941 239,816 14,430,099”
ZIMMER BIOMET HOLDINGS, INC. shareholders approved Ratification of the Appointment of the Independent Registered Public Accounting Firm at the 2024-05-10 meeting.
“Proposal 2 – Ratification of the Appointment of the Independent Registered Public Accounting Firm For Against Abstain Broker Non-Votes 180,021,848 6,535,348 157,574 0”
ZIMMER BIOMET HOLDINGS, INC. shareholders approved Election of Directors at the 2024-05-10 meeting.
“Proposal 1 – Election of Directors Nominee For Against Abstain Broker Non-Votes Christopher B. Begley 164,724,972 7,333,022 226,677 14,430,099 Betsy J. Bernard 162,760,822 9,396,081 127,768 14,430,099 Michael J. Farrell 167,518,122 4,633,274 133,275 14,430,099 Robert A. Hagemann 162,464,750 9,591,079 228,842 14,430,099 Arthur J. Higgins 166,306,021 5,846,729 131,921 14,430,099 Maria Teresa Hilado 169,774,488 2,389,765 120,418 14,430,099 Syed Jafry 170,362,310 1,786,113 136,248 14,430,099 Sreelakshmi Kolli 162,271,545 9,878,950 134,176 14,430,099 Louis Shapiro 171,579,592 573,252 131,827 14,430,099 Ivan Tornos 169,580,110 2,565,650 138,911 14,430,099”
ZIMMER BIOMET HOLDINGS, INC. updated its full-year 2024 guidance (reaffirmed).
“The Company is reiterating its current full-year 2024 financial guidance. Projected Year Ending December 31, 2024 2024 Reported Revenue Change 4.5% - 5.5% Foreign Currency Exchange Impact (0.5)% 2024 Constant Currency Revenue Change 5.0% - 6.0% Adjusted Diluted EPS (1) $8.00 - $8.15”
ZIMMER BIOMET HOLDINGS, INC. reported quarter ended March 31, 2024 results: revenue $1.889 billion, net income $172.4 million, EPS $0.84.
“The Company reported first quarter net sales of $1.889 billion, an increase of 3.2% over the prior year period, and an increase of 4.4% on a constant currency 1 basis. Net earnings for the first quarter were $172.4 million, or $399.7 million on an adjusted 1 basis. Diluted earnings per share were $0.84 for the first quarter, and adjusted 1 diluted earnings per share were $1.94.”
ZIMMER BIOMET HOLDINGS, INC. reported year ending December 31, 2024 results: revenue 2024 Reported Revenue Change 4.5% - 5.5%, EPS Adjusted Diluted EPS $8.00 - $8.15. Guidance reaffirmed.
“The Company is providing the following full-year 2024 financial guidance: Projected Year Ending December 31, 2024 2024 Reported Revenue Change 4.5% - 5.5%”
ZIMMER BIOMET HOLDINGS, INC. reported quarter and year ended December 31, 2023 results: revenue Fourth quarter net sales of $1.940 billion; Full-year net sales of $7.394 billion, net income Net earnings for the fourth quarter were $419.2 million; For the full year, net earnings were $1.024 billion, EPS Diluted earnings per share were $2.01 for the fourth quarter; Full-year diluted earnings per share were $4.88.
“heather.zoumaslubeski@zimmerbiomet.com zach.weiner@zimmerbiomet.com Zimmer Biomet Announces Fourth Quarter and Full-Year 2023 Financial Results • Fourth quarter net sales of $1.940 billion increased 6.3% and 6.1% on a constant currency 1 basis • Fourth quarter diluted earnings per share were $2.01; adjusted 1 diluted earnings per share were $2.20 • Full-year net”
Louis A. Shapiro was appointed as Director at ZIMMER BIOMET HOLDINGS, INC..
“On January 5, 2024, the Board of Directors (the “Board”) of Zimmer Biomet Holdings, Inc. (the “Company”), upon the recommendation of the Corporate Governance Committee, increased the size of the Board from ten members to eleven members and appointed Louis A. Shapiro to fill the resulting vacancy, with a term to expire at the Company’s 2024 annual meeting of shareholders.”
ZIMMER BIOMET HOLDINGS, INC. incurred senior notes of $500.0 million aggregate principal amount with Barclays Capital Inc., Goldman Sachs & Co. LLC, Mizuho Securities USA LLC and Morgan Stanley & Co. LLC at 5.350% per annum maturing December 1, 2028.
“USA LLC and Morgan Stanley & Co. LLC, as representatives of the underwriters named therein (collectively, the “Underwriters”), in connection with the public offering of $500.0 million aggregate principal amount of the Company’s 5.350% Note due 2028 (the “Notes”). The issuance of the Notes was completed on December 1, 2023. The Underwriting Agreement contains”
ZIMMER BIOMET HOLDINGS, INC. entered into Ninth Supplemental Indenture with Computershare Trust Company, N.A. (effective 2023-12-01).
“The Notes were issued pursuant to the Ninth Supplemental Indenture dated as of December 1, 2023 (the “Supplemental Indenture”), to the Company’s Indenture (the “Base Indenture”) dated as of November 17, 2009, between the Company and Computershare Trust Company, N.A., as successor to Wells Fargo Bank, National Association, as trustee.”
ZIMMER BIOMET HOLDINGS, INC. entered into Underwriting Agreement with Barclays Capital Inc., Goldman Sachs & Co. LLC, Mizuho Securities USA LLC and Morgan Stanley & Co. LLC valued at $500.0 million aggregate principal amount (effective 2023-11-28).
“On November 28, 2023, Zimmer Biomet Holdings, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Barclays Capital Inc., Goldman Sachs & Co. LLC, Mizuho Securities USA LLC and Morgan Stanley & Co. LLC, as representatives of the underwriters named therein (collectively, the “Underwriters”), in connection with the public offering of $500.0 million aggregate principal amount of the Company’s 5.350% Note due 2028 (the “Notes”).”
ZIMMER BIOMET HOLDINGS, INC. reported financial results for the quarter ended September 30, 2023.
“On November 7, 2023, Zimmer Biomet Holdings, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended September 30, 2023.”
Suketu Upadhyay was appointed as Chief Financial Officer and Executive Vice President – Finance, Operations and Supply Chain at ZIMMER BIOMET HOLDINGS, INC..
“Additionally, effective August 22, 2023, Suketu Upadhyay has been appointed to the newly-created position of Chief Financial Officer and Executive Vice President – Finance, Operations and Supply Chain.”
Christopher B. Begley was appointed as Chairman of the Board at ZIMMER BIOMET HOLDINGS, INC..
“Effective August 22, 2023, the Board appointed Christopher B. Begley, who has been a director of the Company since 2012 and the Lead Independent Director since May 2021, to be the Chairman of the Board.”
Ivan Tornos was elected as Member of the Board of Directors at ZIMMER BIOMET HOLDINGS, INC..
“Effective August 22, 2023, the Board appointed Ivan Tornos the Company’s President and Chief Executive Officer, and elected Mr. Tornos a member of the Board of Directors to fill the vacancy resulting from Mr. Hanson’s departure from the Board.”
Ivan Tornos was appointed as President and Chief Executive Officer at ZIMMER BIOMET HOLDINGS, INC..
“Effective August 22, 2023, the Board appointed Ivan Tornos the Company’s President and Chief Executive Officer, and elected Mr. Tornos a member of the Board of Directors to fill the vacancy resulting from Mr. Hanson’s departure from the Board.”
Bryan C. Hanson departed as Chairman of the Board, President and Chief Executive Officer at ZIMMER BIOMET HOLDINGS, INC..
“On August 17, 2023, Bryan C. Hanson notified the Company that he planned to step down as Chairman of the Board, President and Chief Executive Officer of the Company and as a member of the Company’s Board, all effective as of August 22, 2023.”
ZIMMER BIOMET HOLDINGS, INC. reported financial results for the quarter ended June 30, 2023.
“On August 1, 2023, Zimmer Biomet Holdings, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended June 30, 2023.”
ZIMMER BIOMET HOLDINGS, INC. incurred revolving credit of $1.0 billion with JPMorgan Chase Bank, N.A. at adjusted Term SOFR plus an applicable margin maturing July 5, 2024.
“The 364-Day Revolving Credit Agreement, dated as of July 7, 2023, among the Company, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the “364-Day Credit Agreement”), is an unsecured revolving credit facility in the principal amount of $1.0 billion (the “364-Day Revolving Facility”).”
ZIMMER BIOMET HOLDINGS, INC. incurred revolving credit of $1.5 billion with JPMorgan Chase Bank, N.A. at adjusted Term SOFR plus an applicable margin maturing July 7, 2028.
“On July 7, 2023, Zimmer Biomet Holdings, Inc. (the “Company”) entered into a new five-year revolving credit agreement and a new 364-day revolving credit agreement, as described below. The Five-Year Revolving Credit Agreement, dated as of July 7, 2023, among the Company, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the “Five-Year Credit Agreement”), is a five-year unsecured revolving facility of $1.5 billion (the “Five-Year Revolving Facility”).”
ZIMMER BIOMET HOLDINGS, INC. terminated 2022 364-Day Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent (effective 2023-07-07).
“The Five-Year Revolving Credit Agreement, dated as of July 7, 2023, among the Company, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the “Five-Year Credit Agreement”), is a five-year unsecured revolving facility of $1.5 billion (the “Five-Year Revolving Facility”).”
ZIMMER BIOMET HOLDINGS, INC. terminated 2022 Five-Year Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent valued at $520.0 million (effective 2023-07-07).
“There was $520.0 million in aggregate outstanding borrowings under the 2022 Five-Year Credit Agreement at the time it was terminated, which borrowings were repaid through borrowings on July 7, 2023 in the same amounts and on the same terms under the Five-Year Credit Agreement.”
ZIMMER BIOMET HOLDINGS, INC. entered into 364-Day Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent valued at $1.0 billion (effective 2023-07-07).
“The 364-Day Revolving Credit Agreement, dated as of July 7, 2023, among the Company, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the “364-Day Credit Agreement”), is an unsecured revolving credit facility in the principal amount of $1.0 billion (the “364-Day Revolving Facility”).”
ZIMMER BIOMET HOLDINGS, INC. entered into Five-Year Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent valued at $1.5 billion (effective 2023-07-07).
“The Five-Year Revolving Credit Agreement, dated as of July 7, 2023, among the Company, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the “Five-Year Credit Agreement”), is a five-year unsecured revolving facility of $1.5 billion (the “Five-Year Revolving Facility”).”
ZIMMER BIOMET HOLDINGS, INC. shareholders approved Advisory vote on frequency of future say-on-pay votes at the 2023-05-12 meeting.
“Proposal 4 – Advisory Vote on the Frequency of Future Say on Pay Votes One Year Two Years Three Years Abstain Broker Non-Votes 168,589,917 209,817 2,185,659 237,765 14,759,329”
ZIMMER BIOMET HOLDINGS, INC. shareholders approved Advisory vote to approve named executive officer compensation at the 2023-05-12 meeting.
“Proposal 3 – Advisory Vote to Approve Named Executive Officer Compensation (“Say on Pay”) For Against Abstain Broker Non-Votes 154,324,848 16,581,269 317,041 14,759,329”
ZIMMER BIOMET HOLDINGS, INC. shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for 2023 at the 2023-05-12 meeting.
“Proposal 2 – Ratification of the Appointment of the Independent Registered Public Accounting Firm For Against Abstain Broker Non-Votes 179,645,610 6,107,827 229,050 0”
ZIMMER BIOMET HOLDINGS, INC. shareholders approved Election of ten directors for one-year terms ending at the 2024 annual meeting at the 2023-05-12 meeting.
“Proposal 1 – Election of Directors Nominee For Against Abstain Broker Non-Votes Christopher B. Begley 166,908,825 4,050,882 263,451 14,759,329 Betsy J. Bernard 164,016,923 6,968,137 238,098 14,759,329 Michael J. Farrell 168,494,216 2,483,935 245,007 14,759,329 Robert A. Hagemann 161,196,003 9,763,336 263,819 14,759,329 Bryan C. Hanson 162,902,982 7,752,853 567,323 14,759,329 Arthur J. Higgins 161,684,103 9,290,615 248,440 14,759,329 Maria Teresa Hilado 169,301,785 1,693,759 227,614 14,759,329 Syed Jafry 168,570,075 2,405,034 248,049 14,759,329 Sreelakshmi Kolli 170,133,224 844,303 245,631 14,759,329 Michael W. Michelson 168,557,967 2,419,477 245,714 14,759,329”
ZIMMER BIOMET HOLDINGS, INC. reported full-year 2023 results: EPS $7.40 - $7.50. Guidance raised.
“Projected Year Ending December 31, 2023 Previous Guidance Updated Guidance 2023 Reported Revenue Change 1.5% - 3.5% 5.0% - 6.0% Foreign Currency Exchange Impact (1.5)% (1.0)% Adjusted Diluted EPS (1) $6.95 - $7.15 $7.40 - $7.50”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.